Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Preserving lean muscle mass during GLP-1 therapy requires deliberate protein intake, resistance training, and metabolic monitoring—not just calorie reduction. Research shows that 20–30% of weight loss on GLP-1 medications can be lean tissue loss rather than fat, especially in the first 6 months of therapy.

PlexusDx supports precision wellness by helping you understand your individual metabolic predispositions before starting GLP-1 treatment. Knowing your genetic profile in key peptide pathways may provide context for how aggressively your body responds to these medications, enabling you and your provider to design a muscle-sparing strategy from day one.

Start your GLP-1 program with PlexusDx

One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.

Start your intake →

Why Muscle Loss Accelerates on GLP-1 Medications

GLP-1 receptor agonists reduce appetite significantly, leading to caloric deficit. Without intentional protein and strength training, your body breaks down muscle tissue for energy—a process called proteolysis. This is more pronounced in patients with lower baseline muscle mass or those losing weight rapidly.

The metabolic shift is real: studies document 25–35% lean mass loss in rapid-loss phases without intervention. Older adults and those with sedentary lifestyles face higher risk. Your individual genetics in metabolic and appetite pathways may influence how quickly this occurs, making early prevention critical.

Protein, Exercise, and Biomarker Targets for Muscle Preservation

Maintaining muscle requires three pillars: adequate protein intake (1.6–2.2 g/kg body weight), resistance training 3–4 times weekly, and monitoring key biomarkers. Creatinine, albumin, prealbumin, and nitrogen balance provide objective measures of muscle status during GLP-1 therapy.

Preservation Strategy Clinical Target / Dosing
Protein Intake 1.6–2.2 g/kg body weight daily; distribute across meals
Resistance Training Frequency 3–4 sessions per week, 45–60 minutes; emphasize compound lifts
Biomarker Monitoring Serum albumin >3.5 g/dL; prealbumin >20 mg/dL; creatinine baseline comparison
Caloric Deficit Rate 1–1.5 lbs per week maximum; faster losses increase proteolysis risk

Genetic Predispositions That Influence Your Muscle-Loss Risk

Variations in genes controlling appetite signaling (GIPR) and metabolic rate (FTO, MC4R) may predispose you to more or less aggressive appetite suppression and energy expenditure on GLP-1 therapy. These predispositions don't determine your outcome—but they may help contextualize your individual response pattern.

The Precision Peptide Genetic Test evaluates predispositions in four key peptide pathway variants. Understanding your genetic profile can support a more informed conversation with your provider about starting protein targets, exercise intensity, and biomarker monitoring frequency before rapid muscle loss occurs.

Who Should Prioritize Muscle Preservation, and When to Reassess

Muscle preservation becomes urgent for older adults (60+), those with baseline lean mass deficits, athletes, or patients losing more than 2 lbs per week. Reassess your strategy every 4–6 weeks by tracking body composition, strength metrics, and biomarkers—not weight alone. Your provider should evaluate whether dose adjustment or medication timing is needed.

If you're starting GLP-1 therapy for the first time, discuss your muscle-preservation plan with your clinician before beginning medication. Baseline biomarker testing, genetic insights from the Precision Peptide Test, and a strength-training template reduce the likelihood of excessive lean mass loss and improve long-term metabolic outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GIPR, FTO, and MC4R pathways—genes linked to appetite regulation and metabolic rate. This information, interpreted with your healthcare provider, can inform how aggressively you address protein and exercise before starting GLP-1 therapy.

The genetic test reveals predispositions in peptide signaling pathways, not exact medication response or guaranteed muscle-preservation outcomes. Some patients with certain genetic profiles may experience more pronounced appetite suppression, making protein and resistance training even more critical. Your provider should integrate this context into your personalized treatment plan.

By identifying your genetic predispositions early, you and your provider can establish baseline biomarkers, set realistic protein and exercise targets, and monitor progress more closely—enabling a truly personalized approach to preserving lean mass during GLP-1 therapy rather than reactive adjustments months into treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much muscle do people actually lose on GLP-1 medications?

Clinical studies show 20–35% of weight loss can be lean tissue rather than fat, especially in the first 6 months without intentional preservation strategies. Individual variation is significant and influenced by starting body composition, exercise habits, and protein intake.

What protein amount is needed to prevent muscle loss on GLP-1?

Evidence supports 1.6–2.2 grams of protein per kilogram of body weight daily. Distribute protein across meals to optimize muscle protein synthesis, and pair with resistance training for maximum preservation effect.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx offers the Precision Peptide Genetic Test for $298. It evaluates predispositions in GIPR, FTO, and MC4R—genes linked to appetite and metabolism—to provide context for your provider's personalized approach.

What biomarkers should I monitor during GLP-1 therapy?

Key biomarkers include serum albumin (target >3.5 g/dL), prealbumin (>20 mg/dL), creatinine baseline comparison, and nitrogen balance. Request these labs every 4–6 weeks if you're losing weight rapidly to catch muscle loss early.

Does compounded semaglutide or tirzepatide cause more muscle loss than branded versions?

Muscle-loss risk depends on appetite suppression intensity and individual adherence to protein/exercise, not whether the medication is compounded or branded. PlexusDx compounded semaglutide and tirzepatide are formulated by licensed 503A pharmacies and carry the same preservation considerations as any GLP-1 therapy.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.